ArticleBiomaterials2019
Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease.
Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Antigen-specific immunotherapy with a CD4Nature communications · 2026Article
- Regulatory T cells in autoimmune diseases: biological mechanisms, clinical translation, and translational challenges.Frontiers in immunology · 2026Review
- Remote loading of an autoantigen in PLGA nanoparticles for the treatment of multiple sclerosis.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non-Responders to Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Anti-TNF-α antisense-oligonucleotide-conjugated PLG nanoparticles protect transplanted islets.Molecular therapy. Methods & clinical development · 2025Article
- Engineering immunity using metabolically active polymeric nanoparticles.Trends in biotechnology · 2025Review
- Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Biodegradable Electrospun PLGA Nanofibers-Encapsulated Trichinella Spiralis Antigens Protect from Relapsing Experimental Autoimmune Encephalomyelitis and Related Gut Microbiota Dysbiosis.International journal of nanomedicine · 2025Article
- Bridging the gender gap in autoimmunity with T-cell-targeted biomaterials.Current opinion in biotechnology · 2024Review
- Physicochemical Property Effects on Immune Modulating Polymeric Nanoparticles: Potential Applications in Spinal Cord Injury.International journal of nanomedicine · 2024Review
- Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance.Nanomaterials (Basel, Switzerland) · 2023Review
- Cell and biomaterial delivery strategies to induce immune tolerance.Advanced drug delivery reviews · 2023Review
- Optimization and characterization of miRNA-129-5p-encapsulated poly (lactic-Nanoscale advances · 2023Article
- Vaccines in Breast Cancer: Challenges and Breakthroughs.Diagnostics (Basel, Switzerland) · 2023Review
- Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity.Advanced nanobiomed research · 2023Article
- Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance.Advanced healthcare materials · 2023Review
- Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance.Nature communications · 2022Article
- Immunomodulatory Strategies for Spinal Cord Injury.Biomedical journal of scientific & technical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Current therapeutic options for autoimmune diseases, such as multiple sclerosis (MS), often require lifelong treatment with immunosuppressive drugs, yet strategies for antigen-specific immunomodulation are emerging. Biodegradable particles loaded with disease-specific antigen, either alone or with immunomodulators, have been reported to ameliorate disease. Herein, we hypothesized that the carrier could impact polarization of the immune cells that associate with particles and the subsequent disease progression. Single injection of three polymeric carriers, 50:50 poly (DL-lactide-co-glycolide) (PLG) with two molecular weights (Low, High) and poly (DL-lactide) (PLA), loaded with the disease-specific antigen, proteolipid protein (PLP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.